Marilyn C. Pike

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

Michael Simons, Brian H. Annex, Roger J. Laham et al. · Circulation · 2002 · 650 citations

Medicine, Cardiology, Pharmacotherapy +17

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Daniel J. Wallace, Kenneth Kalunian, Michelle Petri et al. · Annals of the Rheumatic Diseases · 2013 · 338 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure

Raimund Hirschberg, Joel D. Kopple, Pamela Lipsett et al. · Kidney International · 1999 · 305 citations · Full text

Medicine, Endocrinology, Nephrology +10

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

Eric F. Morand, Marilyn C. Pike, Joan T. Merrill et al. · Arthritis & Rheumatology · 2022 · 248 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 236 citations · Full text

Life Sciences, Clinical Sciences, Immunology +17